Ninety five patients with small cell carcinoma of the lung were randomly assigned to one of two chemotherapy regimens (VACE or CVACE), each consisting of six cycles at three week intervals. The VACE regimen consisted of six cycles of vincristine 1'2 mg/m2, doxorubicin 40 mg/m2, and cyclophosphamide 700 mg/m2 on day 1 plus etoposide 110 mg/m2 daily for three days.
etoposide 110 mg/m2 daily for three days.
The CVACE regimen was identical to the VACE regimen for cycles 3 and 4; cycles 1, 2, 4, and 6 consisted of etoposide 110 mg/m2 for three days plus cisplatin 100 mg/m2 with mannitol diuresis on the second day. Forty eight patients received VACE and 47 CVACE. Side effects resulted in withdrawal of four patients receiving VACE and six receiving CVACE. Three deaths were attributed to VACE and one to CVACE. Median survival did not differ between the two treatments overall, though there was a small increase in median survival in partial responders receiving CVACE. It is concluded that replacing four of the six cycles of VACE (vincristine, doxorubicin, cyclophosphamide, and etoposide) with Patients who had not responded were withdrawn three weeks after cycle four (that is, when cycle five was due) and considered for alternative treatment, which in most cases consisted of radiotherapy. Complete responders after cycle 6 were randomly allocated to a group receiving prophylactic cranial irradiation and to a no treatment group. Partial responders received further chemotherapy (with mitomycin C and procarbazine) or radiotherapy or no further treatment depending on individual circumstances. Dose modifications were made in the event Does the substitution of cisplatin in a standardfour drug regimen improve survival in small cell carcinoma of the lung? Ninety five patients entered the study, of whom 47 were randomised to receive CVACE and 48 VACE; of these patients, 40 and 38 respectively were given four or more cycles of treatment.
WITHDRAWALS
Of the 17 patients receiving less than four cycles, five had received VACE, three having 
Survival in weeks
Survival curves comparing patients receiving VACE (vincristine, dox cyclophosphamide, and etoposide) with those receiving CVA CE (cisp cycles in place of vincristine, doxorubicin, and cyclophosphamide-see "Protocol"). The number ofpatients receiving prophylactic cranial irradiation in this study was too small to permit any definite conclusion. Our results do not suggest that this approval is likely to be a solution to the widespread problem of death from cerebral metastases in patients with remissions that are otherwise complete.
Our results show that replacing VAC with cisplatin and etoposide for four out of six treatment cycles confers no advantage in terms of survival or of toxicity. The small differences we saw between the two treatment groups suggest that non-alternating VACE without cisplatin may be the better treatment. There is no justification for the increased expense and inconvenience of using cisplatin in induction treatment for small cell lung cancer.
